The Royal Marsden NHS Foundation Trust

Sutton SM25NG

5 studies enrolling now · 36 studies all time

What they study most

Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Advanced Breast Cancer, Advanced Cancer, Advanced Gastric Cancer, Advanced Solid Tumor, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation, Bladder Cancer, Breast Adenocarcinoma, Breast Cancer, Breast Cancer Female

Studies at this site

• A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201) — Recruiting now
• NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer — Recruiting now
• A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) — Recruiting now
• Adoptive Cell Therapy Long-term Follow-up (LTFU) Study — Recruiting now
• A Study of MGC026 in Participants With Advanced Solid Tumors — Recruiting now
• Study of GS-4528 in Adults With Solid Tumors — Running, not enrolling
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Running, not enrolling
• A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors — Running, not enrolling
• A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer — Running, not enrolling
• A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma — Running, not enrolling
• A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors — Stopped early
• Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer — Completed
• Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) — Stopped early
• Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC — Stopped early
• Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers — Completed
• Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma — Completed
• Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma — Running, not enrolling
• Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia — Completed
• Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer — Completed
• An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants — Stopped early
• Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated — Stopped early
• Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer — Completed
• Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy — Completed
• A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma — Completed
• Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) — Completed
• A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC — Status unconfirmed
• Derazantinib and Atezolizumab in Patients With Urothelial Cancer — Completed
• An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML) — Completed
• A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100) — Completed
• Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma — Completed
• Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors — Completed
• Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma — Completed
• A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) — Stopped early
• A Degarelix Trial in Patients With Prostate Cancer — Stopped early
• A Trial of Degarelix in Patients With Prostate Cancer — Completed
• A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy. — Completed